Autifony Therapeutics ranked #44 on the Sifted 250

Autifony Therapeutics is proud to announce that it has been ranked #44 on the Sifted 250, the definitive annual ranking of Europe’s fastest-growing start-ups and scaleups. Sponsored by Zoom, the list identifies the top 250 companies across Europe achieving the highest revenue growth over the past three years, calculated by a two-year Compound Annual Growth Rate (CAGR).

The final rankings were officially unveiled live at the Sifted Summit in London.

Securing the 44th spot highlights Autifony’s strong momentum and commercial growth, this recognition places the company alongside Europe’s most innovative market leaders and disruptive scaleups.

We are thrilled to be recognized by Sifted as one of Europe’s top growth companies, landing at #44 is a direct reflection of our team’s relentless hard work, our ground-breaking scientific advancements, and our strategic vision. This milestone validates our trajectory and fuels our commitment to driving innovation forward.

To view the complete rankings and explore the insights behind this year’s top-performing companies, you can view the official Sifted 250 Leaderboard  and download the comprehensive Sifted 250 Report.